Fakeeh Care delineates acquisition cost of stake in Diagnostics Elite

Dr. Soliman Abdel Kader Fakeeh Hospital Co. (Fakeeh Care) and its subsidiaries stated that the total investment cost of acquiring a 50.01% ownership stake in Diagnostics Elite Co. amounts to SAR 70 million. The former owner of the stake was Soliman Abdul-Qader Fakeeh Real Estate Co. (Fakeeh Real Estate).

The deal comprises SAR 55.35 million to be paid in cash to Fakeeh Real Estate for the transfer of 30,510 shares in Diagnostics Elite to Fakeeh Care. This amount includes SAR 52.3 million, representing the total amounts previously paid by Fakeeh Real Estate to the founders of Diagnostics Elite and for capital increases, and SAR 3.05 million in cost of capital employed by the former owner during this investment period.

Moreover, Fakeeh Care is obliged to directly inject SAR 14.65 million into the capital of Diagnostics Elite to fund its expansion plans, in accordance with the existing share purchase agreements.

In a statement to Tadawul, the company said that Fakeeh Real Estate will transfer these existing shares to Fakeeh Care at a price equivalent to the cost of its investment, following the completion of the necessary regulatory procedures.

It noted that an independent financial valuation estimated the indicative fair value of the 50.01% stake in Diagnostics Elite in the range of SAR 114–125 million.

Accordingly, the total transaction value of SAR 70 million reflects a discount of approximately 38%–44% compared to this indicative fair value range.

According to data available with Argaam, Fakeeh Care signed, on Dec. 2, 2025, a share purchase agreement to acquire 50.01% of Diagnostics Elite, a Saudi company specializing in teleradiology and diagnostic imaging services, for SAR 70 million, including purchase and capital contribution.

Under the agreement, Fakeeh Care will acquire 30,510 shares of Diagnostics Elite, representing 50.01% of the company’s issued capital, at cost and without any profit to the seller.

The remaining 49.99% of shares will continue to be owned by the company’s current founders.